目的:探讨hs-CRP及NT- proBNP在慢性肺源性心脏病(PHD )中的变化及其意义.方法:将97例慢性阻塞性肺疾病(COPD)患者分为3组,检测单纯COPD组(A组 28例)、COPD并发PHD代偿期组(B组 36例)和COPD并发PHD失代偿期组(C组 33 例)hs-CRP 及NT-proBNP值及COPD并发失代偿期PHD患者治疗后hs-CRP及NT- proBNP值.结果:3组患者hs-CRP及NT- proBNP值有极显著性差异( P < 0.01),hs-CRP及NT- proBNP值为:C 组> B 组> A 组.COPD并发失代偿期PHD患者治疗前与治疗后比较有极显著性差异 (P < 0.01).结论:hs-CRP水平增高与PHD的发生、发展显著相关,对判断COPD患者病情及预后有指导意义.NT-proBNP浓度能较好反应COPD患者是否并发PHD及心功能状态.%Objective:To study the change and the significance of hs-CRP and NT-proBNP in the patients with chronic pulmonary heart disease(PHD). Methods: We recruited 97 patients in the same period after they received a diagnosis of COPD and divided them in to 3 groups. Group A contained 28 patients who had pure COPD. Group B contained 36 patients who had COPD, combined with chronic pulmonaryheart disease during compensatory stage. Group C contained 33 patients who had COPD combined with chronic pulmonary heart disease during decom-pensatory stage. We measured hs-CRP and NT-proBNP in plasma in these 97 patients and then analyzed the differences of its level among the 3 groups. Results: There were significant differences among hs-CRP and NT-proBNP levels in plasma of the 3 groups (P<0. 01). Each group of COPD patients hs-CRP, NT- proBNP serum level were: C group> B group> A group. After the therapy, the hs-CRP, NT-ProBNP serum levels significantly decreased with statistically differences (P<0. 01). Conclusion: The increased hs-CRP levels are correlated with the occurring and developing of chronic pulmonary heart disease. The measurement of plasma NT-proBNP levels in patients with COPD can be used to identify whether they are combined with chronic pulmonary heart disease or heart insufficiency or not.
展开▼
